A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)

Trial Profile

A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs AT 406 (Primary) ; Carboplatin; Paclitaxel
  • Indications Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Debiopharm
  • Most Recent Events

    • 23 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jan 2016 Planned number of patients changed from 72 to 31 as reported by ClinicalTrials.gov record.
    • 15 Jan 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top